1. Zhang J, Li X, Huang L: Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment. Adv Drug Deliv Rev 2020, 154-155:245-273.
2. Feng X, Cao S, Qiu F, Zhang B: Traditional application and modern pharmacological research of Artemisia annua L. Pharmacol Ther 2020, 216:107650.
3. Akin EJ, Alsaloum M, Higerd GP, Liu S, Zhao P, Dib-Hajj FB, Waxman SG, Dib-Hajj SD: Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021.
4. Yin S, Qiu Y, Jin C, Wang R, Wu S, Liu H, Koo S, Han L, Zhang Y, Gao X, et al: 7-Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma. Int J Cancer 2019, 145:3334-3346.
5. Wang H, Yang S, Zhou H, Sun M, Du L, Wei M, Luo M, Huang J, Deng H, Feng Y, et al: Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms. J Hematol Oncol 2015, 8:26.
6. Sun D, Tao W, Zhang F, Shen W, Tan J, Li L, Meng Q, Chen Y, Yang Y, Cheng H: Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling. Signal Transduct Target Ther 2020, 5:174.
7. Wang D, Wang Y, Zhao G, Zhuang J, Wu W: Improving systemic circulation of paclitaxel nanocrystals by surface hybridization of DSPE-PEG2000. Colloids Surf B Biointerfaces 2019, 182:110337.
8. Hu J, Dong Y, Ding L, Dong Y, Wu Z, Wang W, Shen M, Duan Y: Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct Target Ther 2019, 4:28.
9. Yu H, Qiu Y, Pang X, Li J, Wu S, Yin S, Han L, Zhang Y, Jin C, Gao X, et al: Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma. Mol Cancer Ther 2017, 16:2711-2723.
10. Wu S, Qiu Y, Shao Y, Yin S, Wang R, Pang X, Ma J, Zhang C, Wu B, Koo S, et al: Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3. Front Pharmacol 2018, 9:881.
11. Roy M, Liang L, Xiao X, Feng P, Ye M, Liu J: Lycorine: A prospective natural lead for anticancer drug discovery. Biomed Pharmacother 2018, 107:615-624.
12. Sun Y, Wu P, Sun Y, Sharopov FS, Yang Q, Chen F, Wang P, Liang Z: Lycorine possesses notable anticancer potentials in on-small cell lung carcinoma cells via blocking Wnt/beta-catenin signaling and epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun 2018, 495:911-921.
13. Hu M, Yu Z, Mei P, Li J, Luo D, Zhang H, Zhou M, Liang F, Chen R: Lycorine Induces autophagy-associated apoptosis by targeting MEK2. Aging 2020, 12:1.
14. Liu J, Wang Y, Qiu Z, Lv G, Huang X, Lin H, Lin Z, Qu P: Impact of TCM on Tumor-Infiltrating Myeloid Precursors in the Tumor Microenvironment. Front Cell Dev Biol 2021, 9:635122.
15. Wang C, Li L, Zhang S, Yan Y, Huang Q, Cai X, Xiao J, Cheng Y: Carrier-Free Platinum Nanomedicine for Targeted Cancer Therapy. Small 2020, 16:e2004829.
16. Zhu L, Guo Y, Qian Q, Yan D, Li Y, Zhu X, Zhang C: Carrier-Free Delivery of Precise Drug-Chemogene Conjugates for Synergistic Treatment of Drug-Resistant Cancer. Angew Chem Int Ed Engl 2020, 59:17944-17950.
17. Zhang N, Li M, Sun X, Jia H, Liu W: NIR-responsive cancer cytomembrane-cloaked carrier-free nanosystems for highly efficient and self-targeted tumor drug delivery. Biomaterials 2018, 159:25-36.
18. Supper E, Rudat S, Iyer V, Droop A, Wong K, Spinella JF, Thomas P, Sauvageau G, Adams DJ, Wong CC: Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia. Nat Commun 2021, 12:2482.
19. Ligeon LA, Pena-Francesch M, Vanoaica LD, Nunez NG, Talwar D, Dick TP, Munz C: Oxidation inhibits autophagy protein deconjugation from phagosomes to sustain MHC class II restricted antigen presentation. Nat Commun 2021, 12:1508.
20. Klatt Shaw D, Saraswathy VM, Zhou L, McAdow AR, Burris B, Butka E, Morris SA, Dietmann S, Mokalled MH: Localized EMT reprograms glial progenitors to promote spinal cord repair. Dev Cell 2021, 56:613-626 e617.
21. Wu T, Wang C, Wang W, Hui Y, Zhang R, Qiao L, Dai Y: Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis. Oncoimmunology 2018, 7:e1498437.
22. Schafer M, Semmler ML, Bernhardt T, Fischer T, Kakkassery V, Ramer R, Hein M, Bekeschus S, Langer P, Hinz B, et al: Small Molecules in the Treatment of Squamous Cell Carcinomas: Focus on Indirubins. Cancers (Basel) 2021, 13.
23. Liang Q, Cai W, Zhao Y, Xu H, Tang H, Chen D, Qian F, Sun L: Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. Pharmacol Res 2020, 158:104884.
24. Li C, Deng C, Pan G, Wang X, Zhang K, Dong Z, Zhao G, Tan M, Hu X, Shi S, et al: Lycorine hydrochloride inhibits cell proliferation and induces apoptosis through promoting FBXW7-MCL1 axis in gastric cancer. J Exp Clin Cancer Res 2020, 39:230.
25. Zhang P, Zhang M, Yu D, Liu W, Hu L, Zhang B, Zhou Q, Cao Z: Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of beta-catenin and matrix metallopeptidase 9. J Cell Physiol 2019, 234:10566-10575.
26. Guo Y, Liu X, Sun X, Zhang Q, Gong T, Zhang Z: Mannosylated lipid nano-emulsions loaded with lycorine-oleic acid ionic complex for tumor cell-specific delivery. Theranostics 2012, 2:1104-1114.
27. Wong KE, Ngai SC, Chan KG, Lee LH, Goh BH, Chuah LH: Curcumin Nanoformulations for Colorectal Cancer: A Review. Front Pharmacol 2019, 10:152.
28. Liu X, Kang J, Wang H, Huang T, Li C: Construction of Fluorescein Isothiocyanate-Labeled MSNs/PEG/Lycorine/Antibody as Drug Carrier for Targeting Prostate Cancer Cells. J Nanosci Nanotechnol 2018, 18:4471-4477.
29. Sun J, Li Y, Teng Y, Wang S, Guo J, Wang C: NIR-controlled HSP90 inhibitor release from hollow mesoporous nanocarbon for synergistic tumor photothermal therapy guided by photoacoustic imaging. Nanoscale 2020, 12:14775-14787.
30. Damasco JA, Chen G, Shao W, Agren H, Huang H, Song W, Lovell JF, Prasad PN: Size-tunable and monodisperse Tm(3)(+)/Gd(3)(+)-doped hexagonal NaYbF(4) nanoparticles with engineered efficient near infrared-to-near infrared upconversion for in vivo imaging. ACS Appl Mater Interfaces 2014, 6:13884-13893.
31. Li Y, Lin J, Cai Z, Wang P, Luo Q, Yao C, Zhang Y, Hou Z, Liu J, Liu X: Tumor microenvironment-activated self-recognizing nanodrug through directly tailored assembly of small-molecules for targeted synergistic chemotherapy. Journal of Controlled Release 2020, 321:222-235.
32. Li Y, Lin J, Wang P, Luo Q, Lin H, Zhang Y, Hou Z, Liu J, Liu X: Tumor Microenvironment Responsive Shape-Reversal Self-Targeting Virus-Inspired Nanodrug for Imaging-Guided Near-Infrared-II Photothermal Chemotherapy. ACS Nano 2019, 13:12912-12928.
33. Li Y, Liu G, Ma J, Lin J, Lin H, Su G, Chen D, Ye S, Chen X, Zhu X, Hou Z: Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy. Journal of Controlled Release 2017, 258:95-107.
34. Wen Y, Zhang W, Gong N, Wang YF, Guo HB, Guo W, Wang PC, Liang XJ: Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo. Nanoscale 2017, 9:14347-14356.
35. Park J, Sun B, Yeo Y: Albumin-coated nanocrystals for carrier-free delivery of paclitaxel. J Control Release 2017, 263:90-101.
36. Zhao Z, Xiang S, Qi J, Wei Y, Zhang M, Yao J, Zhang T, Meng M, Wang X, Zhou Q: Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy. Cell Death Dis 2020, 11:387.
37. Roy M, Liang L, Xiao X, Peng Y, Luo Y, Zhou W, Zhang J, Qiu L, Zhang S, Liu F, et al: Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma. Theranostics 2016, 6:2209-2224.
38. Hayden RE, Pratt G, Drayson MT, Bunce CM: Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance. Haematologica 2010, 95:1889-1896.
39. Maimon A, Levy-Yahid V, Ben-Meir2 K. Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10, J Clin Invest, 85 (2021) 1-40.
40. Zhang B, Li Y, Wu Q, Xie L, Barwick B, Fu C, Li X, Wu D, Xia S, Chen J, et al: Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nat Commun 2021, 12:1714.
41. Yang S, Li H, Yao H, Zhang Y, Bao H, Wu L, Zhang C, Li M, Feng L, Zhang J, et al: Long noncoding RNA ERLR mediates epithelial-mesenchymal transition of retinal pigment epithelial cells and promotes experimental proliferative vitreoretinopathy. Cell Death Differ 2021.
42. Cui YH, Yang S, Wei J, Shea CR, Zhong W, Wang F, Shah P, Kibriya MG, Cui X, Ahsan H, et al: Autophagy of the m(6)A mRNA demethylase FTO is impaired by low-level arsenic exposure to promote tumorigenesis. Nat Commun 2021, 12:2183.
43. Rosenfeldt MT, O'Prey J, Lindsay CR, Nixon C, Roth S, Sansom OJ, Ryan KM: Loss of autophagy affects melanoma development in a manner dependent on PTEN status. Cell Death Differ 2021, 28:1437-1439.
44. Lv Y, Zhang W, Zhao J, Sun B, Qi Y, Ji H, Chen C, Zhang J, Sheng J, Wang T, et al: SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct Target Ther 2021, 6:108.